Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2004-09-17
2008-09-16
McGarry, Sean R (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S024100, C536S024500, C536S023100, C435S006120, C435S375000, C435S377000
Reexamination Certificate
active
07425544
ABSTRACT:
Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided.
REFERENCES:
patent: WO 02/44321 (2000-06-01), None
patent: WO 01/96388 (2001-12-01), None
patent: WO 02/10409 (2002-02-01), None
patent: WO 2004113496 (2004-12-01), None
Rychlik, et al., “Amino acid sequence of the mRNA cap-binding protein from human tissues,”Proc. Natl. Acad. Sci.,84:945-949 (Feb. 1987).
Altmann, K-H, et al., “Novel Chemistry”,Applied Antisense Oligonucleotide Technology(Stein & Krieg, Eds.), pp. 73-107, Wiley-Liss: New York (1998).
De Benedetti, Arrigo, et al., “eIF4E expression in tumors: Its possible role in progression of malignancies”,Int'l Journal of Biochemistry and Cell Biology,31(1):59-72 (Jan. 1999).
Vickers, Timothy, et al., “Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents,”Journal of Biological Chemistry,278(9):7108-7118 (2003).
Yamagiwa, Yoko, et al., “Translational regulation by p38 mitogen-activated protein kinase signaling during human cholangiocarcinoma growth,”Hepatology,38(1):158-166 (Jul. 2003).
Yang, Yu-Jie, et al., “Contribution of eIF-4E inhibition to the expression and activity of heparanase in human colon adenocarcinoma cell line : LS-174T,”World J. Gastroenterol,9(8):1707-1712 (2003).
Zimmer, S., et al., “Translational Control of Malignancy: the mRNA cap-Binding Protein, eIF-4E, as a Central Regulator of Tumor Formation, Growth, Invasion and Metastasis,”Anticancer Research,20:1343-1352 (2000).
J.R. Graff et al., Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity,The Journal of Clinical Investigation,Sep. 2007, pp. 2638-2648, vol. 117, No. 9.
B.C. Barnhart et al., Taking aim at translation for tumor therapy,The Journal of Clinical Investigation,Sep. 2007, pp. 2385-2388, vol. 117, No. 9.
S.T. Crooke, Progress in Antisense Technology,Annual Review of Medicine: Selected Topics in the Clinical Sciences,2004, pp. 61-95, vol. 55.
De Benedetti, A., et al., “Expression of antisense RNA against Initiation Factor eIF-4E mRNA in HeLa Cells Results in Lengthened Cell Division Times, Diminished Translation Rates, and Reduced Levels of Both eIF-4E and the p220 Component of eIF-4F,”Molecular and Cellular Biology 11(11):5435-5445 (1991).
De Benedetti, A., et al., “Expression of Antisense RNA Against eIF-4E mRNA in HeLa Cells Results in Diminished Translation Rates, Lengthened Doubling Time, and a Requirement for eIF-4F in vitro,”FASEB Journal,75th Annual Meeting, Atlanta, GA, Apr. 21-25, 1991 Abstracts Part III, Abstract 6760:A1536 (1991).
De Benedetti, A., et al., “eIF-4E expression and its role in malignancies and metastases,”Oncogene 23:3189-3199 (2004).
Meric, F., et al., “Translation Initiation in Cancer: A Novel Target for Therapy,”Molecular Cancer Therapeutics1:971-979 (2002).
eIF-4E Antisense Oligonucleotide Sequence Search Results (2003; 2004).
GenBank Record for Accession No. BU747458 (2002).
GenBank Record for Accession No. BG074412 (2001).
GenBank Record for Accession No. M15353.1 (1987).
GenBank Record for Accession No. NM—007917.1 (1991).
Jaramillo, M. et al., “Multiple mRNAs Encode the Murine Translation Initiation Factor eIF-4E,”The Journal of Biological Chemistry 266(16):10446-10451 (1991).
Scherer et al., Approaches for the sequence-specific knockdown of mRNA,Nature Biotechnology21(12):1457-1465 (2003).
Mahato et al., Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA,Expert Opinion on Drug Delivery2(1):3-28 (2005).
Groothuis, The blood-brain and blood-tumor barriers: A review of strategies for increasing drug delivery,Neuro-Oncology2(1):45-59 (2000).
Jen et al., Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies,Stem Cells18:307-319 (2000).
Matzura et al., RNAdraw; an integrated program for RNA secondary structure calculation and analysis under 32-bit Microsoft Windows,Computer Applications in the Biosciences12(3):247-249 (1996).
Olie et al., A Novel Antisense Oligonucleotide Targeting Survivin Expression Induces Apoptosis and Sensitizes Lung Cancer Cells to Chemotherapy,Cancer Research60:2805-2809 (2000).
Bhat Balkrishen
Dobie Kenneth
Graff Jeremy Richard
Marcusson Eric G.
Swayze Eric E.
Cohen Charles E.
Eli Lilly and Company
ISIS Pharmaceuticals Inc.
McGarry Sean R
LandOfFree
Modulation of eIF4E expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of eIF4E expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of eIF4E expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3987189